Novel oral anticoagulants in oral and maxillofacial surgery: a comparison with warfarin between 2012-2014
DOI:
https://doi.org/10.22024/UniKent/03/ajpp.359Palavras-chave:
Bleeding, New anticoagulants, Rivaroxaban, Warfarin, SurgeryResumo
The records of anticoagulated patients who attended a maxillofacial surgical unit between 2012 and 2014 were reviewed. Data on 319 procedures performed on 249 patients were retrieved. During this period only seven patients (2.8%) were taking novel anticoagulants (NOACs) compared with 242 (97.2%) on warfarin. The seven patients underwent 11 surgical procedures. None of the seven were seen in 2012, three were seen in January 2013, the remaining four in 2014. Twenty-four (7.5%) of the 319 episodes were followed by prolonged bleeding; all occurred in patients taking warfarin. The seven NOAC patients’ hospital notes contained no recorded documentation of renal function, specifically the creatinine clearance or estimated glomerular filtration rate.Referências
Griffiths M, Scully C. New anticoagulants. Brit Dent J 2012;13: 96.
Breik O, Cheng A, Sambrook P, Goss A. Protocol in managing oral surgical patients taking dabigatran. Aust Dent J 2014; 59: 296–301.
Pradaxa. Prescribers guide 2015. Available at: http://products.boehringer-ingelheim.com/pradaxa/sites/default/files/Prescriber_guide.pdf (Accessed: 10 May 2016).
Nice.org.uk. (2016). Reversal of the anticoagulant effect of dabigatran: idarucizumab | key-points-from-the-evidence | Advice | NICE. [online]. Available at: https://www.nice.org.uk/advice/esnm73/chapter/key-points-from-the evidence [accessed 27/11/2016].
Green B, Mendes R, van der Valk R, Brennan P. Novel anticoagulants - an update on the latest developments and management for clinicians treating patients on these drugs. J Oral Pathol Med 2016; 45: 551-556.
Sime G. [Online] Available at: http://www.sigwales.org/wp-content/uploads/dental-management-of-patients-taking-anticoagulant-drugs-outside-a-general-hospital-setting.pdf [Accessed 13 May 2016].
Gonsalves WI, Pruthi RK, Patnaik MM. The new oral anticoagulants in clinical practice. Mayo Clin Proc 2013; 88: 495–511.
Scottish Dental Clinical Effectiveness Programme. [Online] Management of dental patients taking anticoagulants or antiplatelet drugs. Available at: http://www.sdcep.org.uk/wp-content/uploads/2015/09/SDCEP-Anticoagulants-Guidance.pdf (Accessed: 1st February 2016).
Elad S, Marshall J, Meyerowitz C, Connolly G. Novel anticoagulants: general overview and practical considerations for dental practitioners. Oral Diseases 2016; 22: 23–32.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
AJPP requests that, as the creator(s)/author(s) of the manuscript you are submitting, that you assign certain rights to the manuscript to the AJPP in exchange for undertaking to publish the article in electronic form and, in general, to pursue its dissemination throughout the world. The rights the AJPP requests are:
- The right to publish the article in electronic form or in any other form it may choose that is in keeping with its role as a scholarly journal with the goal of disseminating the work as widely as possible;
- The right to be the sole publisher of the article for a period of 12 months;
- The right to make the article available to the public within a period of not more than 24 months, as determined by relevant journal staff of the AJPP;
- The right to grant republication rights to itself or others in print, electronic, or any other form, with any revenues accrued to be shared equally between the author(s) and the journal;
- The right to administer permission to use portions of the article as requested by others, seeking recompense when the AJPP sees it as warranted;
- The right to seek or take advantage of opportunities to have the article included in a database aimed at increasing awareness of it;
- As the author(s), the AJPP wishes you to retain the right to republish the article, with acknowledgement of the AJPP as the original publisher, in whole or in part, in any other pbulication of your own, including any anthology that you might edit with up to three others;
- As the author(s), the AJPP wishes you to retain the right to place the article on your personal Web page or respository of your university or institution. The AJPP askes that you include this notice: A fully edited, peer-reviewed version of this article was first published by the Advanced Journal of Professional Practice, <Year>, <Volume>, <Issue>, <Page Numbers>.
- You retain the right to unrestricted use of your paper for yourself or for your own teaching purposes.
BY AGREEING TO THE FOREGOING, YOU CONFIRM THAT THE MANUSCRIPT YOU ARE SUBMITTING HAS NOT BEEN PUBLISHED ELSEWHERE IN WHOLE OR IN PART, AND THAT NO AGREEMENT TO PUBLISH IS OUTSTANDING.
SHOULD THE ARTICLE CONTAIN MATERIAL WHICH REQUIRES WRITTEN PERMISSION FOR INCLUSION, YOU AGREE THAT IT IS YOUR OBLIGATION IN LAW TO IDENTIFY SUCH MATERIAL TO THE EDITOR OF THE AJPP AND TO OBTAIN SUCH PERMISSION. THE AJPP WILL NOT PAY ANY PERMISSION FEES. SHOULD THE AJPP BE OF THE OPINION THAT SUCH PERMISSION IS NECESSARY, IT WILL REQUIRE YOU TO PURSUE SUCH PERMISSSION PRIOR TO PUBLICATION.
AS AUTHOR(S), YOU WARRANT THAT THE ARTICLE BEING SUBMITTED IS ORIGINAL TO YOU.
Provided the foregoing terms are satisfactory, and that you are in agreement with them, please indicate your acceptance by checking the appropriate box and proceed with your submission.
